Drug intelligence / Profile preview

HAT-10

Development stage: Preclinical
Lead developer: DRC
Administration: Topical

Overview

HAT-10 is a medical device developed by the Japanese company DRC Co., Ltd. (DRC Iyaku). It is designed as a topical sheet for the treatment and management of pressure ulcers (bedsores) and is categorized within the company's infectious disease pipeline. The device is currently in the preclinical and validation trial phase in Japan. Its sheet-like formulation suggests a wound dressing or barrier function intended to facilitate healing or prevent infection in chronic skin lesions.

Beyond the preview

Go deeper on HAT-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAT-10.

Explore the full profile